Why is the Paradigm (ASX:PAR) share price climbing today?

The Paradigm (ASX: PAR) share price is up 2.8% after the company reported a loss in its first-half FY21 earnings. Here's a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price gained ground today and is presently trading at $2.55 a share, a 2.82% bounce.

The share price increase comes after Paradigm released its 1HY21 financial results.

Here's the rundown of what we found out. 

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

Paradigm share price rises after company reports loss

Paradigm reported a net profit after taxes (NPAT) loss of $20.7 million for 1HY21. This compares to the $5.1 million loss reported for 1HY20.

The company advised that the increased NPAT loss was a product of the significant progress made with its osteoarthrosis (OA) and mucopolysaccharidosis (MPS) clinical programs.

Specifically, the company incurred the costs and expenses reflected in the NPAT loss in order to launch phase II and phase III trials for the treatment of MPS. Paradigm also allocated additional expenses to convene meetings pertaining to OA with the United States Food and Drug Administration and European Medicines Agency.

As of 31 December 2020, Paradigm posted $95.3 million worth of assets. $112.4 million in total assets was reported for the 1HY20 period.

Cash and cash equivalents totalled $85.2 million for 1HY21 compared to $80 million for 1HY20.

The company received a $3.4 million R&D tax incentive during 1Hy21.

Chief medical officer shares insight

Paradigm chief medical officer Dr Donna Skerrett commented on Paradigm's progress during the period, saying: 

During CY 2020, Paradigm conducted a number of non-clinical and clinical studies to provide updated information regarding drug characteristics, pharmacokinetics, and non-clinical toxicity as requested by the FDA in the company's first meeting with the agency in February 2020.

Paradigm has worked diligently to ensure it has all the necessary supporting non-clinical and clinical data and clinical development plan to support its IND submission in Q1 CY 2021.

Paradigm share price snapshot

Over the past year, the Paradigm share price has dropped about 26%.

The company's market capitalisation is $578.2 million. Paradigm currently has 225.9 million shares outstanding.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A smiling boy holds a toy plane aloft while a girl watches on from a car near an airport runway.
Broker Notes

3 ASX 200 shares tipped to return 27% to 87%

These stocks could really take off.

Read more »

Investor sitting in front of multiple screens watching share prices
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It looks set to be a better day for Aussie investors.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
ASX Share Market News

$10,000 invested in BHP and CBA shares three years ago is now worth…

Here’s how the returns from BHP and CBA shares stack up over the past three years.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
ASX Share Market News

Buy, hold sell: Telstra, Origin Energy & Westpac shares

One of these ASX shares is likely to fall from here, according to experts.

Read more »

Two young risk-taking men pose for the camera as they jump off a cliff into the sea.
ASX Share Market News

2 ASX shares tipped by brokers to return 25% and 42%

There is plenty of potential for growth ahead.

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

Let's take a look.

Read more »

A little girl has a huge smile and a giant lollipop.
Broker Notes

6 ASX shares tipped by brokers to rise 34% to 87%

Post-earnings season, brokers have updated their 12-month price targets on scores of stocks.

Read more »

Happy businessman fist pumping while looking at a tablet.
Broker Notes

2 ASX shares tipped to return 19% to 47%

Recent sell-offs have caught Morgans’ attention, with the broker now rating both shares as buys.

Read more »